Gossamer Bio (GOSS) Competitors

Gossamer Bio (NASDAQ:GOSS) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, community ranking, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Which has stronger valuation and earnings, GOSS or GLSI?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	N/A	N/A	-$179.82M	-$1.39	-0.56
Greenwich LifeSciences	N/A	N/A	-$7.82M	-$0.70	-17.24

Do institutionals & insiders have more ownership in GOSS or GLSI?

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 9.5% of Gossamer Bio shares are held by company insiders. Comparatively, 52.9% of Greenwich LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Do analysts prefer GOSS or GLSI?

Gossamer Bio currently has a consensus target price of $7.65, suggesting a potential upside of 876.01%. Greenwich LifeSciences has a consensus target price of $36.00, suggesting a potential upside of 198.26%. Given Gossamer Bio's higher probable upside, equities analysts plainly believe Gossamer Bio is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Greenwich LifeSciences	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is GOSS or GLSI more profitable?

Greenwich LifeSciences' return on equity of -80.50% beat Gossamer Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	N/A	-944.79%	-67.76%
Greenwich LifeSciences	N/A	-80.50%	-78.56%

Does the media prefer GOSS or GLSI?

In the previous week, Greenwich LifeSciences had 3 more articles in the media than Gossamer Bio. MarketBeat recorded 3 mentions for Greenwich LifeSciences and 0 mentions for Gossamer Bio. Greenwich LifeSciences' average media sentiment score of 0.31 beat Gossamer Bio's score of 0.00 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Gossamer Bio	Neutral
Greenwich LifeSciences	Neutral

Does the MarketBeat Community believe in GOSS or GLSI?

Gossamer Bio received 137 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 64.84% of users gave Gossamer Bio an outperform vote while only 33.33% of users gave Greenwich LifeSciences an outperform vote.

Company	Underperform	Outperform
Gossamer Bio	Outperform Votes 142 64.84%	Underperform Votes 77 35.16%
Greenwich LifeSciences	Outperform Votes 5 33.33%	Underperform Votes 10 66.67%

Which has more risk and volatility, GOSS or GLSI?

Gossamer Bio has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.

Summary

Gossamer Bio beats Greenwich LifeSciences on 8 of the 15 factors compared between the two stocks.